Lymphoma/CLL Highlights: ASH 2021

CME

Key Studies in Lymphomas and CLL: Independent Conference Coverage of ASH 2021

Physicians: Maximum of 1.25 AMA PRA Category 1 Credits

Released: May 10, 2022

Expiration: May 09, 2023

John M. Burke
John M. Burke, MD
Peter Martin
Peter Martin, MD

Activity

Progress
1
Course Completed

References

  1. Tilly H, Morschhauser F, Sehn LH, et al. The POLARIX study: polatuzumab vedotin with rituximab, cyclophosphamide, doxorubicin, and prednisone (pola-R-CHP) versus rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) therapy in patients with previously untreated diffuse large B-cell lymphoma. Presented at: 63rd American Society of Hematology Annual Meeting; December 11-14, 2021. Abstract LBA-1.
  2. Tilly H, Morschhauser F, Sehn LH, et al. Polatuzumab vedotin in previously untreated diffuse large B-cell lymphoma. N Engl J Med. 2022;386:351-363.
  3. Polatuzumab prescribing information. South San Francisco, CA: Genentech, Inc.; 2020.
  4. Tilly H, Morschhauser F, Bartlett NL, et al. Polatuzumab vedotin in combination with immunochemotherapy in patients with previously untreated diffuse large B-cell lymphoma: an open-label, non-randomized, phase 1b-2 study. Lancet Oncol. 2019;20:998-1010.
  5. Roschewski M, Dunleavy K, Pittaluga S, et al. Circulating tumor DNA and CT monitoring in patients with untreated diffuse large B-cell lymphoma: a correlative biomarker study. Lancet Oncol. 2015;16:541-549.
  6. Kumar A, Westin JR, Schuster SJ, et al. A prospective multicenter study of minimal residual disease assessment using a next-generation immunosequencing assay and CT monitoring for surveillance after frontline treatment in diffuse large B-cell lymphoma. Presented at: 63rd American Society of Hematology Annual Meeting; December 11-14, 2021. Abstract 52.
  7. Locke FL, Miklos DB, Jacobson CA, et al. Axicabtagene ciloleucel as second-line therapy for large B-cell lymphoma. N Engl J Med. 2022;386:640-654.
  8. Bishop MR, Dickinson M, Purtill D, et al. Tisagenlecleucel vs standard of care as second-line therapy of primary refractory or relapsed aggressive B-cell non-Hodgkin lymphoma: analysis of the phase III BELINDA study. Presented at: 63rd American Society of Hematology Annual Meeting; December 11-14, 2021. Abstract LBA-6.
  9. Bishop MR, Dickinson M, Purtill D, et al. Second-line tisagenlecleucel or standard care in aggressive B-cell lymphoma. N Engl J Med. 2022;386:629-639.
  10. Locke FL, Miklos DB, Jacobson C, et al. Primary analysis of ZUMA‑7: a phase 3 randomized trial of axicabtagene ciloleucel (axi-cel) versus standard‑of‑care therapy in patients with relapsed/refractory large B-cell lymphoma. Presented at: 63rd American Society of Hematology Annual Meeting; December 11-14, 2021. Abstract 2.
  11. Locke FL, Ghobadi A, Jacobson CA, et al. Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicenter, phase 1-2 trial. Lancet Oncol. 2019;20:31-42.
  12. Kamdar M, Solomon SR, Arnason JE, et al. Lisocabtagene maraleucel (liso-cel), a CD19-directed chimeric antigen receptor (CAR) T cell therapy, versus standard of care (SOC) with salvage chemotherapy (CT) followed by autologous stem cell transplantation (ASCT) as second-line (2L) treatment in patients (pts) with relapsed or refractory (R/R) large B-cell lymphoma (LBCL): results from the randomized phase 3 TRANSFORM study. Presented at: 63rd American Society of Hematology Annual Meeting; December 11-14, 2021. Abstract 91.
  13. Ishida T, Utsunomiya A, Jo T, et al. Mogamulizumab for relapsed adult T-cell leukemia-lymphoma: Updated follow-up analysis of phase I and II studies. Cancer Sci. 2017;108:2022-2029.
  14. Yoshimitsu M, Izutsu K, Makita S, et al. Pivotal phase 2 study of the EZH1 and EZH2 inhibitor valemetostat tosylate (DS-3201b) in patients with relapsed or refractory adult T-cell leukemia/lymphoma. Presented at: 63rd American Society of Hematology Annual Meeting; December 11-14, 2021. Abstract 303.
  15. Budde LE, Sehn LH, Matasar M, et al. Mosunetuzumab monotherapy is an effective and well-tolerated treatment option for patients with relapsed/refractory (R/R) follicular lymphoma (FL) who have received ≥2 prior lines of therapy: pivotal results from a phase I/II study. Presented at: 63rd American Society of Hematology Annual Meeting; December 11-14, 2021. Abstract 127.
  16. Schuster SJ, Dickinson MJ, Dreyling MH, et al. Efficacy and safety of tisagenlecleucel (tisa-cel) in adult patients (pts) with relapsed/refractory follicular lymphoma (r/r FL): Primary analysis of the phase 2 ELARA trial. Presented at: 2021 American Society of Clinical Oncology Meeting; June 4-8, 2021. Abstract 7508.
  17. Thieblemont C, Dickinson M, Martinez-Lopez J, et al. Efficacy of tisagenlecleucel in adult patients (pts) with high-risk relapsed/refractory follicular lymphoma (r/r FL): subgroup analysis of the phase II Elara study. Presented at: 63rd American Society of Hematology Annual Meeting; December 11-14, 2021. Abstract 131.
  18. Lynch RC, Avigdor A, McKinney MS, et al. Efficacy and safety of parsaclisib in patients with relapsed or refractory follicular lymphoma: primary analysis from a phase 2 study (CITADEL-203). Presented at: 63rd American Society of Hematology Annual Meeting; December 11-14, 2021. Abstract 813.
  19. Mehta A, Trněný M, Walewski J, et al. Efficacy and safety of parsaclisib in patients with relapsed or refractory mantle cell lymphoma not previously treated with a BTK inhibitor: primary analysis from a phase 2 study (CITADEL-205). Presented at: 63rd American Society of Hematology Annual Meeting; December 11-14, 2021. Abstract 382.
  20. Hillmen P, Eichhorst B, Brown JR, et al. First interim analysis of ALPINE study: results of a phase 3 randomized study of zanubrutinib vs ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma. Presented at: 26th Congress of the European Hematology Association; June 10-13, 2021. Abstract LB1900.
  21. Tam CS, Giannopoulos K, Jurczak W, et al. SEQUOIA: results of a phase 3 randomized study of zanubrutinib versus bendamustine + rituximab (BR) in patients with treatment-naïve (TN) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). Presented at: 63rd American Society of Hematology Annual Meeting; December 11-14, 2021. Abstract 396.
  22. Woyach JA, Ruppert AS, Heerema NA, et al. Ibrutinib regimens versus chemoimmunotherapy in older patients with untreated CLL. New Engl J Med 2018;379:2517-2528.
  23. Wierda WG, Tam CS, Allan JN, et al. Ibrutinib (ibr) plus venetoclax (ven) for first-line treatment of chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL): 1-year disease-free survival (DFS) results from the MRD cohort of the phase 2 CAPTIVATE study. ASH 2020 Presented at: 62nd American Society of Hematology Annual Meeting; December 5-8, 2020. Abstract 123.
  24. Wierda WG, Allan JN, Siddiqi T, et al. Ibrutinib plus venetoclax for first-line treatment of chronic lymphocytic leukemia: primary analysis results from the minimal residual disease cohort of the randomized phase II CAPTIVATE study. J Clin Oncol. 2021;39:3853-3865.
  25. Ghia P, Allan JN, Siddiqi T, et al. First-line treatment with ibrutinib (ibr) plus venetoclax (ven) for chronic lymphocytic leukemia (CLL): 2-year post-randomization disease-free survival (DFS) results from the minimal residual disease (MRD) cohort of the phase 2 CAPTIVATE study. Presented at: 63rd American Society of Hematology Annual Meeting; December 11-14, 2021. Abstract 68.
  26. Munir T, Moreno C, Owen C, et al. First prospective data on minimal residual disease (MRD) outcomes after fixed-duration ibrutinib plus venetoclax (Ibr+Ven) versus chlorambucil plus obinutuzumab (Clb+O) for first-line treatment of CLL in elderly or unfit patients: the GLOW study. Presented at: 63rd American Society of Hematology Annual Meeting; December 11-14, 2021. Abstract 70.
  27. Kater A, Owen C, Moreno C, et al: Fixed duration ibrutinib and venetoclax versus chlorambucil plus obinutuzumab for first-line chronic lymphocytic leukemia: Primary analysis of the phase 3 GLOW study. Presented at: 26th Congress of the European Hematology Association; June 10-13, 2021. Abstract LB1902.
  28. Woyach JA, Flinn IW, Awan FT, et al. Preliminary efficacy and safety of MK-1026, a non-covalent inhibitor of wild-type and C481S mutated Bruton tyrosine kinase, in B-cell malignancies: a phase 2 dose expansion study. Presented at: 63rd American Society of Hematology Annual Meeting; December 11-14, 2021. Abstract 392.
  29. Mato AR, Shah NN, Jurczak W, et al. Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 study. Lancet. 2021;397:892-901.
  30. Seymour JF, Byrd JC, Hillmen P, et al. Characterization of Bruton tyrosine kinase inhibitor (BTKi)-related adverse events in a head-to-head trial of acalabrutinib versus ibrutinib in previously treated chronic lymphocytic leukemia (CLL). Presented at: 63rd American Society of Hematology Annual Meeting; December 11-14, 2021. Abstract 3721.
  31. Byrd JC, Hillmen P, Ghia P, et al. First results of a head-to-head trial of acalabrutinib versus ibrutinib in previously treated chronic lymphocytic leukemia. Presented at: 2021 American Society of Clinical Oncology Meeting; June 4-8, 2021. Abstract 7500.